(SoC)

Cardiff Oncology Reports Results of Onvansertib in P-Ib/II Trial for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer

Shots: The P-Ib/II trial evaluates the safety and preliminary efficacy of onvansertib + Folfiri and Avastin in 2L treatment of patients with KRAS-mutated mCRC As of July 2, 2021, 42% patients achieved a partial response at RP2D (15 mg/m2 dose); confirmed PR (37%); ORR (5-13%); mPFS has not yet reached. Additionally, 38% patients achieved an …

Cardiff Oncology Reports Results of Onvansertib in P-Ib/II Trial for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer Read More »

Targovax Reports Results of ONCOS-102 in P-l/ll Study as 1L and 2L Treatment for Malignant Pleural Mesothelioma

Shots: The exploratory P-l/ll study involves the assessment of ONCOS-102 + SoC CT (pemetrexed/cisplatin) as a 1L and 2L treatment in 31 patients with MPM Result: @18mos. follow up showed that mOS (18.2mos. vs 14.2mos.) and showed broad and powerful immune activation, associated with better survival outcome. The next survival analysis is planned in H1’21 …

Targovax Reports Results of ONCOS-102 in P-l/ll Study as 1L and 2L Treatment for Malignant Pleural Mesothelioma Read More »